Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines in oncology, autoimmune disease and inflammatory conditions. The NRIX news feed on Stock Titan aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how its pipeline and collaborations evolve over time.
News about Nurix frequently centers on clinical trial results and milestones for its lead programs. Recent releases describe new and updated data from Phase 1a/1b studies of the BTK degrader bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, including objective response rates, durability of responses and safety findings. Additional updates cover translational and clinical data for NX-1607, an oral CBL-B inhibitor for solid tumors, highlighting immune activation, tumor microenvironment remodeling and disease control in heavily pretreated patients.
Investors and clinicians can also use the NRIX news page to track corporate and regulatory events such as the initiation of the pivotal DAYBreak CLL-201 Phase 2 study, plans for a confirmatory Phase 3 trial, expansion of bexobrutideg into autoimmune and inflammatory indications, and participation in major medical and investor conferences including the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC) and the J.P. Morgan Healthcare Conference.
Nurix’s news flow further includes announcements on strategic collaborations and governance, such as progress in partnered STAT6 and IRAK4 degrader programs with Sanofi and Gilead, and board appointments that add drug development and commercialization experience. Bookmark this page to access a consolidated view of NRIX press releases and related coverage as the company advances its targeted protein degradation pipeline.
Nurix Therapeutics announced the appointments of Paula G. O’Connor, M.D., as Chief Medical Officer, and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer.
Dr. O’Connor, with over 15 years of drug development experience, joined Nurix in 2022 and has held senior positions at Protagonist Therapeutics and Genentech. Dr. Phiasivongsa, also joining in 2022, has extensive expertise in CMC development and has held leadership roles at Kronos Bio and Principia Biopharma.
These appointments aim to accelerate the development of Nurix's NX-5948 program targeting B cell malignancies, including chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
Nurix Therapeutics announced a transition in its board leadership. David L. Lacey stepped down as chair, continuing his role as a board member and committee leader. Julia P. Gregory, a current board member since 2019, was unanimously elected as the new board chair. Nurix's CEO, Arthur T. Sands, praised Lacey's guidance and expressed confidence in Gregory's ability to drive the company forward. Gregory brings extensive experience, having held leadership roles at ContraFect , Five Prime Therapeutics, and Lexicon Pharmaceuticals. The company is focused on developing targeted protein modulation drugs for cancer and inflammatory diseases.
Nurix Therapeutics will present new data on their selective BTK degrader, NX-5948, at the European Hematology Association Congress (EHA2024) from June 13-16, 2024, in Madrid, Spain, and virtually.
The data, from an ongoing Phase 1a/b study, show a 70% overall response rate in 10 heavily pretreated CLL patients with resistance mutations to BTK inhibitors. The responses are deepening with longer treatment duration, and all responses are ongoing as of January 2024.
The presentation will also include additional data at higher dose levels and longer treatment durations. Nurix will host a webcast conference call on June 16 following the presentation.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) will participate in the RBC Capital Markets Global Healthcare Conference. Arthur T. Sands, M.D., Ph.D., Nurix's CEO, will be in a fireside chat on May 14, 2024. The event will be webcast live and accessible via the Investors section of the Nurix website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.